Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity

Area of Science:

• Ophthalmology
• Neonatology
• Vascular Biology

Background:

• Retinopathy of prematurity (ROP) is a significant cause of vision impairment in premature infants globally.
• Current treatments like laser therapy for severe ROP have limitations, necessitating novel therapeutic approaches.
• Vascular endothelial growth factor (VEGF) plays a critical role in the development of ROP.

Purpose of the Study:

• To discuss the increasing incidence of ROP worldwide.
• To evaluate the potential of inhibiting the VEGF signaling pathway for treating severe ROP.
• To address concerns associated with broad VEGF inhibition.

Main Methods:

• Review of existing literature on ROP treatments.
• Analysis of animal models of oxygen-induced retinopathy to understand VEGF's role.
• Examination of basic research data on anti-VEGF effects.
• Assessment of the clinical relevance of preclinical findings.

Main Results:

• VEGF signaling is implicated in the pathogenesis of severe ROP.
• Anti-VEGF therapies show promise based on animal studies and basic research.
• Concerns exist regarding the safety and efficacy of broad VEGF inhibition in ROP.

Conclusions:

• Targeting VEGF offers a potential new avenue for treating severe ROP.
• Further clinical research is needed to establish the optimal use of anti-VEGF agents in ROP.
• Balancing the benefits and risks of VEGF inhibition is crucial for clinical application.